Catheter Related Bloodstream Infection (CRBSI) Market Proposal, Demand And Trade Analysis 2023 to 2033

 The Catheter Related Bloodstream Infection (CRBSI) Market is anticipated to reach US$ 44.67 billion in 2023 and US$ 80 billion by 2023 to 2033 at a CAGR of 6%. The rise in the market for catheter-related bloodstream infections can be linked to the rise in the number of persons who experience urine infections. The market for catheter-related bloodstream infections increased historically at a CAGR of 4.5% from 2017 to 2022.

An increasing number of surgeries due to a rise in the number of chronic ailments such as diabetes, cardiovascular disorders, urological disorders, end-stage renal diseases, and other chronic conditions is expected to increase the adoption rate of catheters. This, in tun, is expected to increase the chances of patients suffering from catheter-related bloodstream infection market.

To learn more about this report: https://www.futuremarketinsights.com/reports/catheter-related-bloodstream-infection-crbsi-market

Furthermore, technological advancements play crucial role in fueling the market growth. For instance, miniaturized catheters and introduction of antimicrobial catheters are expected to reduce catheter-associated infections Although major players are innovating, launching and introducing safer catheters, the limited expansion of the same is contributing to the market for catheter-related bloodstream infusions.

Key Takeaways from the Market Study

  • By distribution channel, hospital pharmacies are expected to possess 40% market share for catheter-related bloodstream infections market in 2023.
  • By drug class, antimicrobial catheters are expected to possess 35% market share for catheter-related bloodstream infections in 2023.
  • North America is expected to possess 35% market share for catheter-related bloodstream infection market in 2023.
  • Asia Pacific is expected to possess 30% market share for catheter-related bloodstream infection market in 2023.

“Rise in prevalence of diseases that require catheter are increasing the number of patients suffering from catheter-related bloodstream infections. This, in turn, is supporting the growth of the market.” states a FMI analyst

Competitive Landscape

Key players in the catheter-related bloodstream infection are Xellia Pharmaceuticals Ltd, Pfizer, Glenmark Pharmaceuticals Ltd, Fresenius Medical Care, CorMedix, TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca Pharma India Ltd, Merck Sharp & Dohme Corp

  • In August 2021, Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.
  • In February 2020, CorMedix, Inc. announced that Neutrolin received grant from the U.S. Food and Drug Administration for the prevention of catheter-related bloodstream infections (CRBSIs) in hemodialysis patients.

Central line-associated bloodstream infection (CLABSI) is an infection that occurs when bacteria or other microorganisms enter the bloodstream through a catheter. Catheters are medical devices that are inserted into the body to deliver fluids, medications, or nutrition. They are commonly used in hospitals, long-term care facilities, and in the home for patients who require ongoing medical treatment.

Key Companies Profiled: 

  • Xellia Pharmaceuticals Ltd.
  • Pfizer
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Medical Care
  • CorMedix
  • TauroPhar GmbH
  • Geistlich Pharma
  • Citus Pharmaceuticals
  • AstraZeneca Pharma India Ltd.
  • Merck Sharp & Dohme Corp

Key Segments Profiled in the Catheter-Related Bloodstream Infection Market Industry Survey

Drug Class:

  • Non-antibiotic
  • Anti-infective
  • Antimicrobial

Pathogens:

  • Contaminated Catheter Hub
  • Contaminated Infusate
  • Skin Insertion
  • Hematogenous

Source of Infection:

  • Aureus
  • Aeruginsa
  • CONS
  • Baumanii
  • Coli
  • Pnemoniae
  • Candida sp

Route of Administration:

  • Oral
  • Intravenous

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more